Tütüncü, Serdar http://orcid.org/0000-0002-5057-7487
Olma, Manuel C.
Kunze, Claudia
Dietzel, Joanna
Schurig, Johannes
Rosenkranz, Michael
Stingele, Robert
Maschke, Matthias
Heuschmann, Peter U.
Kirchhof, Paulus
Laufs, Ulrich
Nabavi, Darius G.
Röther, Joachim
Thomalla, Götz
Veltkamp, Roland
Endres, Matthias
Haeusler, Karl Georg
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Extent of routine diagnostic cardiac work-up at certified German stroke units participating in the prospective MonDAFIS study
https://doi.org/10.1186/s42466-023-00246-8
Heart failure, recurrent vascular events and death in patients with ischemic stroke—results of the MonDAFIS study
https://doi.org/10.1007/s11739-024-03594-8
Impact of standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke (MonDAFIS): Rationale and design of a prospective randomized multicenter study
https://doi.org/10.1016/j.ahj.2015.10.010
Funding for this research was provided by:
Bayer Animal Health
Charité - Universitätsmedizin Berlin
Article History
Received: 28 August 2023
Accepted: 20 March 2024
First Online: 15 April 2024
Declarations
:
: PK is listed as inventor on two patents held by the University of Birmingham, Birmingham, UK (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). PK receives research support for basic, translational, and clinical research projects from the EU, British Heart Foundation, Leducq Foundation, the UK Medical Research Council, and German Centre for Cardiovascular Research, from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies in the past. GT has received speakers' honoraria or consulting fees from Amarin, Daichi Sanyo, Acandis, Bayer Healthcare, Boehringer Ingelheim, Covidien, Bristol-Myers Squibb, Portola, Stryker, and Pfizer. DGN has received speakers' honoraria and consulting fees from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Novartis, and Pfizer. JR has received speakers' honoraria and consulting fees from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, and AstraZeneca. UL reports honoraria and reimbursements for lectures, participation in studies, scientific cooperations (with Saarland University, Saarland, Germany), consulting, travel, support (of colleagues), or support of scientific meetings by Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, MSD, Sanofi, and Servier, outside the submitted work. RV reports grants, personal fees, and being a shareholder from Bayer; grants from Boehringer; grants and personal fees from Bristol-Myers Squibb and Pfizer; grants from Daiichi Sankyo, Medtronic, and Biogen; personal fees from Javelin, Abbott, and AstraZeneca; and holding shares in Novartis, outside the submitted work. RV is an investigator of Imperial National Institutes of Health Research Biomedical Research Centre and partially funded by the EU's Horizon 2020 research and innovation programme (grant agreement 754517 [PRESTIGE-AF]). PUH reports grants from Charité, Universitätsmedizin Berlin during study conduct (within MonDAFIS for biometry; member of the scientific board); research grants from the German Ministry of Research and Education, German Research Foundation, the Bavarian State (ministry for science and the arts; within STAAB COVID-19), the EU, Berlin Chamber of Physicians, German Parkinson Society, University Hospital Würzburg, Robert Koch Institute, German Heart Foundation, Federal Joint Committee within the Innovationfond, University Hospital Heidelberg (within RASUNOA-prime; supported by an unrestricted research grant to the University Hospital Heidelberg from Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, and Daiichi Sankyo), and University Göttingen (within FIND-AF(randomised); supported by an unrestricted research grant to the University Göttingen from Boehringer Ingelheim), outside the submitted work. KGH reports speakers' honoraria, consulting fees or lecture honoraria from Abbott, Alexion, AMARIN, AstraZeneca, Bayer Healthcare, Sanofi, Boehringer Ingelheim, Daiichi Sankyo, Pfizer, Bristol-Myers Squibb, Biotronik, Medtronic, Portola, Premier Research, SUN Pharma, WL Gore and Associates, and Edwards Lifesciences, as well as study support by Bayer and Getemed. ME reports grants from Bayer and fees paid to the Charité from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Covidien, Daiichi Sankyo, GlaxoSmithKline, Novartis, Pfizer, and Sanofi. All other authors declare no competing interests outside the submitted work.
: Each individual patient provided written consent for study inclusion and the associated collection of disease-related data. Furthermore, the study protocol was reviewed and positively evaluated by the Ethics Committee of the Charité and also by the individual ethics committees of the investigational centers.